MedTrace Logo

Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy

NCT02003417 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2018-08-14

No results posted yet for this study

Summary

This study will evaluate the proportion of prostate cancer patients receiving external beam radiation therapy (EBRT) and androgen deprivation therapy (ADT) with controlled blood sugars (fasting glucose and hemoglobin A1c), blood pressure, and cholesterol profile (total cholesterol, LDL, HDL, triglycerides) at baseline, 3 months, and 12 months after completing radiation treatment. In addition, receipt of guideline-recommended cardiovascular, primary and preventive care as well as patient-reported quality of life and satisfaction with care among these patients will be evaluated at baseline and 12 months.

Conditions

Sponsors & Collaborators

  • Radiation Therapy Oncology Group

    collaborator NETWORK

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Ronald C Chen, MD, MPH · University of North Carolina at Chapel Hill - Department of Radiation Oncology

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2016-07-31
Completion
2018-05-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02003417 on ClinicalTrials.gov